Loading organizations...
Feldan Therapeutics is a clinical-stage biopharmaceutical company based in Quebec City, Canada, that develops novel therapeutics utilizing its proprietary Feldan Shuttle platform for the intracellular delivery of proteins and peptides. Founded in 2007 by chemical engineer François-Thomas Michaud, the enterprise originally operated as a bioreagent producer before successfully transitioning into a dedicated drug development firm focused on bringing therapeutic applications to market. The company recently secured $12.5 million in Series A financing led by GC Pharma, alongside participation from Stonebridge Ventures and Anges Québec Capital. To support upcoming regulatory filings and broader operational scaling efforts, the organization strengthened its corporate board of directors by appointing pharmaceutical industry veterans David Mazzo and Iain Dukes. Through strategic partnerships and venture capital funding, the firm collaborates with pharmaceutical companies and academic laboratories to commercialize its pipeline.
Feldan Therapeutics has raised $29.0M across 2 funding rounds.
Feldan Therapeutics has raised $29.0M in total across 2 funding rounds.
Feldan Therapeutics has raised $29.0M across 2 funding rounds. Most recently, it raised $16.5M Series B in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 13, 2023 | $16.5M Series B | — | Ugur Gunaydın, Fsit2, GC Cell, GC Holdings, GUY Leblanc | Announced |
| Sep 18, 2018 | $12.5M Series A | Yongjun HUH | Anges Québec Capital, Stonebridge Ventures | Announced |
Feldan Therapeutics has raised $29.0M in total across 2 funding rounds.
Feldan Therapeutics's investors include Ugur Gunaydın, FSIT2, GC Cell, GC Holdings, Guy LeBlanc, Yongjun HUH, Anges Québec Capital, Stonebridge Ventures.